NABRIVA THERAPEUTICS PLC (NBRV) Stock Price, Quote, News and Overview
NASDAQ:NBRV - Nasdaq - IE000OZRGNV6 - Common Stock - Currency: USD
NBRV Quote, Performance and Key Statistics
1.42
0 (0%)
The current stock price of NBRV is 1.42 USD. In the past month the price decreased by -5.96%. In the past year, price decreased by -69.25%.
NBRV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.8 | 836.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.22 | 402.13B | ||
| JNJ | JOHNSON & JOHNSON | 16.39 | 394.22B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.69 | 231.63B | ||
| MRK | MERCK & CO. INC. | 11.95 | 230.88B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.76 | 215.72B | ||
| PFE | PFIZER INC | 8.57 | 151.03B | ||
| SNY | SANOFI-ADR | 13.4 | 134.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.77 | 117.39B | ||
| GSK | GSK PLC-SPON ADR | 7.87 | 75.67B | ||
| ZTS | ZOETIS INC | 27.92 | 74.58B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32 | 44.64B |
Related stock screener links
About NBRV
Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Company Info
NABRIVA THERAPEUTICS PLC
Alexandra House Office 225/227,, The Sweepstakes,, Ballsbridge
DUBLIN 19406 IE
CEO: Theodore Schroeder
Employees: 39
Company Website: https://www.nabriva.com/
Phone: 3536108166640.0
NABRIVA THERAPEUTICS PLC / NBRV FAQ
What is the stock price of NABRIVA THERAPEUTICS PLC today?
The current stock price of NBRV is 1.42 USD.
What is the ticker symbol for NABRIVA THERAPEUTICS PLC stock?
The exchange symbol of NABRIVA THERAPEUTICS PLC is NBRV and it is listed on the Nasdaq exchange.
On which exchange is NBRV stock listed?
NBRV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NABRIVA THERAPEUTICS PLC stock?
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42. Check the NABRIVA THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NABRIVA THERAPEUTICS PLC worth?
NABRIVA THERAPEUTICS PLC (NBRV) has a market capitalization of 4.55M USD. This makes NBRV a Nano Cap stock.
How many employees does NABRIVA THERAPEUTICS PLC have?
NABRIVA THERAPEUTICS PLC (NBRV) currently has 39 employees.
What are the support and resistance levels for NABRIVA THERAPEUTICS PLC (NBRV) stock?
NABRIVA THERAPEUTICS PLC (NBRV) has a resistance level at 1.54. Check the full technical report for a detailed analysis of NBRV support and resistance levels.
Is NABRIVA THERAPEUTICS PLC (NBRV) expected to grow?
The Revenue of NABRIVA THERAPEUTICS PLC (NBRV) is expected to grow by 89.23% in the next year. Check the estimates tab for more information on the NBRV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NABRIVA THERAPEUTICS PLC (NBRV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NBRV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NBRV, evaluating the profitability, health, valuation and growth aspects
- NABRIVA THERAPEUTICS PLC (NBRV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NABRIVA THERAPEUTICS PLC (NBRV) Sales and EPS estimates to see what analysts future expectations are.
- NABRIVA THERAPEUTICS PLC (NBRV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NABRIVA THERAPEUTICS PLC (NBRV) Insider and Institutional Ownership to learn about the owners and their transactions.
- NABRIVA THERAPEUTICS PLC (NBRV) Stock Chart to make your own analysis
- NABRIVA THERAPEUTICS PLC (NBRV) Latest news and press-releases to stay up to date.
Does NABRIVA THERAPEUTICS PLC (NBRV) stock pay dividends?
NBRV does not pay a dividend.
What is the Price/Earnings (PE) ratio of NABRIVA THERAPEUTICS PLC (NBRV)?
NABRIVA THERAPEUTICS PLC (NBRV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.63).
NBRV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBRV. When comparing the yearly performance of all stocks, NBRV is a bad performer in the overall market: 92.64% of all stocks are doing better.
NBRV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBRV. NBRV has a bad profitability rating. Also its financial health evaluation is rather negative.
NBRV Financial Highlights
Over the last trailing twelve months NBRV reported a non-GAAP Earnings per Share(EPS) of -18.63. The EPS increased by 20.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBRV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 40% to NBRV. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 49.57% and a revenue growth 89.23% for NBRV